Skip to main content
Beijing SL Pharmaceutical Co., Ltd. logo

Beijing SL Pharmaceutical Co., Ltd. — Investor Relations & Filings

Ticker · 002038 ISIN · CNE000001L31 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,472 across all filing types
Latest filing 2022-04-25 Capital/Financing Update
Country CN China
Listing Shenzhen Stock Exchange 002038

About Beijing SL Pharmaceutical Co., Ltd.

https://www.slpharm.com.cn

Beijing SL Pharmaceutical Co., Ltd. specializes in the research, development, manufacturing, and commercialization of pharmaceutical products. The company focuses on several therapeutic areas, including cardiovascular and cerebrovascular diseases, oncology, and infectious diseases. Its product portfolio features a range of chemical drugs and active pharmaceutical ingredients (APIs), with key offerings such as clopidogrel bisulfate and amlodipine besylate. Operating with advanced production facilities that adhere to international Good Manufacturing Practice (GMP) standards, the company emphasizes technological innovation and quality control. The organization serves both domestic and international markets, leveraging its integrated R&D platform to develop generic medications and innovative formulations aimed at improving patient outcomes.

Recent filings

Filing Released Lang Actions
北京双鹭药业股份有限公司关于使用自有资金进行短期风险投资事项的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement by Beijing Shuanglu Pharmaceutical Co., Ltd. regarding the use of its own funds for short-term risk investment. It details the investment purpose, amount, objects, internal control measures, risk control, and opinions from independent directors and the supervisory board. The document is a formal public announcement about a financing/investment activity by the company, not a financial report, earnings release, or management discussion. It does not contain financial statements or detailed financial analysis but rather informs shareholders and the market about the company's capital use decision. Therefore, it fits best under the category of Capital/Financing Update (CAP). The document length is under 5,000 characters, but it is not merely announcing the publication of a report; it is itself the announcement of a financing-related decision. Hence, the classification is CAP with high confidence.
2022-04-25 Chinese
北京双鹭药业股份有限公司关于参股公司首次公开发行股票获中国证监会同意注册的公告
Regulatory Filings Classification · 95% confidence The document is a short announcement (641 characters) regarding the approval by the China Securities Regulatory Commission (CSRC) for the registration of a subsidiary company's initial public offering (IPO) on the STAR Market. It references prior announcements and states that the company will disclose further information as required. There are no financial statements or detailed financial data presented. The document serves as a regulatory update about a capital market event (IPO registration approval) rather than a full financial report or detailed capital/financing update. Given its brevity and nature, it fits best as a Regulatory Filing (RNS) rather than a Capital/Financing Update (CAP) or Report Publication Announcement (RPA).
2022-02-09 Chinese
北京双鹭药业股份有限公司关于获得药物临床试验批准通知书的公告
Regulatory Filings Classification · 95% confidence The document is a public announcement from Beijing Shuanglu Pharmaceutical Co., Ltd. regarding the receipt of a drug clinical trial approval notice from the National Medical Products Administration. It details the drug DT678, its clinical trial approval, and the potential impact on the company. The document is short (1247 characters) and serves as an official announcement of regulatory approval rather than a detailed financial or operational report. It does not contain financial statements, management discussion, or detailed report data. Therefore, it is best classified as a Regulatory Filing (RNS), which covers general regulatory announcements and compliance documents that do not fit other specific categories.
2021-12-07 Chinese
北京双鹭药业股份有限公司关于获得药物临床试验批准通知书的公告
Regulatory Filings Classification · 95% confidence The document is a public announcement from Beijing SL Pharmaceutical Co., Ltd. regarding the receipt of a drug clinical trial approval notice from the National Medical Products Administration. It details the drug information, approval details, and potential impact on the company. The document is short (1267 characters) and serves as an official notification about regulatory approval for clinical trials, not a financial report or detailed filing. It does not contain financial data, management changes, or voting results. It is an announcement of a regulatory event related to drug approval, fitting best under Regulatory Filings (RNS) as a general regulatory announcement that does not fit other specific categories.
2021-11-05 Chinese
监事会决议公告
Regulatory Filings Classification · 95% confidence The document is a resolution announcement from the Supervisory Board regarding the approval of the company's 2021 third quarter report. It states that the Supervisory Board has reviewed and approved the 2021 Q3 report, which was disclosed separately on October 28, 2021, with a specific announcement number. The document itself does not contain the actual financial data or the full report but rather confirms the approval and voting results. The document length is short (707 characters), and it references the actual quarterly report published elsewhere. According to the 'Menu vs Meal' rule, this is an announcement related to the report, not the report itself. Therefore, the appropriate classification is Regulatory Filings (RNS), as it is a regulatory announcement about the approval of a quarterly report, not the report itself.
2021-10-27 Chinese
北京双鹭药业股份有限公司关于聘任证券事务代表的公告
Board/Management Information Classification · 95% confidence The document is an announcement regarding the appointment of a securities affairs representative (温杨女士) by the company's board of directors. It includes details about the appointee's qualifications, compliance with regulatory requirements, and contact information. There is no financial data, report, or detailed analysis present. The document is a formal announcement of a management-related change, specifically related to a corporate officer role. Therefore, it fits best under Board/Management Information (MANG). The document length is short and it is not a report or a certification, so it is not RNS or RPA.
2021-10-27 Chinese

Browse filings by year

23 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.